SCHEMBL8964814

SCHEMBL8964814

CN(C)CCN(Cc1ccccc1)c1cccc(C(=O)c2cc(Br)cnc2N)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.45
ADRA2A P08913 3/20 0.45
DRD1 P21728 3/20 0.45
SLC6A4 P31645 3/20 0.45
SLC6A3 Q01959 3/20 0.45
KCNH2 Q12809 3/20 0.45
SLC6A2 P23975 2/20 0.45
ADRA1A P35348 2/20 0.45
HTR2A P28223 2/20 0.45
HRH1 P35367 2/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
OPRK1 P41145 1/20 0.45
LMNA P02545 3/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
GBA1 P04062 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964806 0.89 GBA1 (0.36) GBA1TSHRAPOBEC3AAPOBEC3GDHFR
SCHEMBL9010876 0.76 MKNK1 (0.39) KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL8965341 0.73 OPRK1 (0.40) OPRK1SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1479539 0.72 HTT (0.39) SMN1; SMN2BLMALDH1A1MEN1KMT2A
SCHEMBL1481581 0.70 HTT (0.37) KMT2A
SCHEMBL8963960 0.69 HDAC4 (0.57) LMNASMN1; SMN2MAPK1ALDH1A1HDAC3
SCHEMBL9010927 0.68 ATR (0.38) ALDH1A1HDAC1MEN1KMT2AATR
SCHEMBL1516765 0.67 MAPT (0.61) LMNASMN1; SMN2MAPK1BLMALDH1A1
SCHEMBL9008398 0.66 PRKCQ (0.50) OPRK1OPRM1
SCHEMBL8970084 0.65 PRKCQ (0.49) LMNAKDM4ESMN1; SMN2GBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CHRM2 4735/4885ADRA2A 3715/4885DRD1 4847/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CHRM2 4735/4885ADRA2A 3715/4885DRD1 4847/4885
US-20090124602-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 CHRM2 4735/4885ADRA2A 3715/4885DRD1 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.